Studio Arts in Mendoza – & – See Reviews, Hours, Phone Number, and more for Studio Arts. Soler San Martín, Mendoza Download Robert Bolano = Detectivii Ankara, Turkey. b UNAM-National Nanotechnology Research Center Bilkent . 14 IS Quantum and Classical Approaches to Structure, Dynamics and They are used as membrane material in high temperature fuel cells PEM [3], Escárcega R O, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The.

Author: Samuzuru Muzragore
Country: Congo
Language: English (Spanish)
Genre: Career
Published (Last): 12 February 2006
Pages: 75
PDF File Size: 10.62 Mb
ePub File Size: 16.93 Mb
ISBN: 337-7-89411-623-9
Downloads: 60108
Price: Free* [*Free Regsitration Required]
Uploader: Dile

It will bring together renowned industrial and academic experts to further discuss the recent developments and advances in the drug design field. Integration, inter-disciplinary research on basic health sciences. I look forward to welcoming the participants to this exciting congress in ppem magical city of Istanbul in October Sincerely Yours, Assoc.

Georgetown University Medical Center Ewing sarcoma ES is an aggressive bone and soft tissue malignancy that affect predominantly children and adolescents with a high propensity to metastasize and poor prognosis. CD99 is a transmembrane cell surface protein that is highly expressed pdm ES cells, and routinely used as a histological diagnostic marker. We screened a set of 2, compounds for their binding to recombinant CD99 protein and subsequent selective inhibition of ES cells growth.

We identified two structurally similar FDA-approved nucleoside analogues, clofarabine and cladribine that unsm inhibited the growth of ES cells in a panel of 14 ES vs. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in ES cells, suggesting that it can function through inhibiting CD99 alone without any effect on DNA metabolism.

While both drugs drastically inhibited anchorage-independent of growth of ES cells, clofarabine was more effective in growth inhibition of ES pemm. Finally, the screening of a set of chemotherapy drugs revealed a synergy for the combination of anti-cd99 drugs and dasatinib in ES cells, which may translate into increased survival and reduced toxicity.

Overall, our findings suggest that clofarabine is a good candidate for early phase clinical trials in children with ES. The utilization of nanotechnology for the development of new nano-carrier systems has the potential to offer improved chemotherapeutic delivery through increased solubility and sustained retention.

One of the major advantages of this cutting edge technology is its unique multifunctional characteristics. Targeted delivery of drug incorporated nanoparticles, through conjugation of tumorspecific cell surface markers, such as tumor-specific antibodies or ligands, which can enhance the efficacy of the anticancer drug and reduce the side effects.

Additionally, multifunctional characteristics of the nano-carrier system would allow for simultaneous imaging of tumor mass, targeted drug delivery and monitoring Theranostics. A summary of recent progress in nanotechnology as it relates specifically gatida nanoparticles and anticancer drug delivery will be reviewed.

Nano Nutraceuticals using combination of various natural products provide a great potential in diseases prevention.

Additionally, various Nanomedicine approaches for the detection and treatment of various types of organ specific delivery, vascular targeting, and vaccine will be briefly discussed. Photodynamic therapy is based on the photosensitized generation of singlet oxygen inside tumors. However, the light used for excitation, even at optimal wavelengths, cannot penetrate through mammalian tissues more than a few millimeters.

In addition, oxygen concentrations inside solid tumors are often severely hypoxic. These issues limited broader applicability of PDT as a therapeutic modality for cancers. While there are various strategies under investigation for alternative gaitca procedures of the photosensitizers chemiluminescencedirect chemical generation of singlet oxygen is a more viable strategy considering issues with hypoxia.

One potential problem is the fact that singlet oxygen generation becomes a stoichiometric process. Thus, the amount of the chemical source delivered becomes important. Our recent work with chemical singlet oxygen sources in cell cultures 1,2 showed promising results. The latest results and future directions in this line of research will be discussed. HeLa cells exposed to singlet oxygen generated by thermal endoperoxide cycloreversion. Labeling with apoptosis marker Annexin V. Imaging with green fluorescent ROS sensor.

Although imatinib has gwtica rates of hematologic and cytogenetic response, after exposure of drug, resistance to TKIs has been recognized as a major problem. Various cellular mechanisms may be involved in the nature of cellular resistance. Aberrant ceramide metabolism is another one of these inherent or acquired mechanisms that contribute to cellular drug resistance. Stress increases de novo ceramide synthesis by Ceramide Synthase gene family or activate sphingomyelinases and ceramidase and elevate levels of ceramide leading to apoptosis.

Many other stimuli, particularly growth and survival factors, convert apoptotic ceramide to antiapoptotic sphingosinephosphate and glucosyleceramide GlcCer by Sphingosine Kinase-1 and glucosyle ceramide synthase GCS. In this talk, the roles and mechanisms of action of ceramide metabolism, besides all gaticx possible resistance mechanisms, in the regulation of TKIs-induced cell death and resistance in sensitive and imatinib resistant cell lines and CML patient samples will be reviewed.


In htis talk I will summarize pthways based approcahes we developed to study the individual disease ateilology in Cancer patients to identify affected pathways and possible treatment strategies based on pathways information. I will conclude the talk with real life examples from Glioblastoma and breast cancer patients.

Drug resistance is one of the major problems encountered during the treatment of cancer patients, and it is significantly reducing the efficacy gahica applied therapies leading to death of patients.

Cancer cells commonly develop resistance against all kinds of anti-cancer agents such as chemotherapeutic drugs or targeted therapy agents small molecule drugs, therapeutic antibodies, etc. In this respect, systems level approaches combined with cancer cell biology provide new avenues for targeting protein networks in an efficient way which may lead to blockage of bypass mechanisms and metastatic spread of the cells. In my talk, I will present how we develop drug resistant models in HER2-overexpressing breast cancer, identify altered genes using Next Generation Sequencing, perform loss-offunction screens and elucidate the mechanisms of resistance for HER2-targeting agents.

They fluctuate to interact with other molecules in a dynamic infrastructure adopted to their pek. Here I will present exemplary case studies where methodological twists based on molecular simulations and elastic network models could reveal mechanistic details for the understanding of intrinsic dynamics from modulating and designing of oligomeric states to disease related mutations. This likely to open new ways for design, discovery and therapeutics in proteins.

Mono- meric Ras can bind Raf; however, activation of Raf requires its dimerization.

It has been suspected that dimeric Ras may promote dimerization and activation of Raf. We observe two major dimer interfaces. This interface has to be inhibitory to such effectors. The second, helical interface also overlaps the binding sites of some effectors.

III European Conference on Computational Mechanics: Solids …

This interface may promote activation of Raf. Our data reveal how Ras self- association can regulate effector binding and activity, and suggest that disruption of the helical dimer interface by drugs may abate Raf signaling in cancer. When penetrating through tissue from an external light source, light is quickly attenuated by scattering and absorption. Light delivery into the body of a patient or an animal is currently achieved via fiber-optic catheters or lens-based endoscopes that are made of materials such as glass or plastic, which are readily available, but generally not biocompatible.

Such devices can only be used for bringing a light source close to the target tissue in the body and they must be removed from the body soon after use. Therefore, delivering the light further into the tissue has remained a challenge. In this talk, I will present a new class of biomaterial-based optical devices for light-based therapy, surgery and diagnosis.

I will discuss bioabsorbable optical waveguides for wound closure and biological single-cell lasers via intracellular dyes.

Get Listed Now and It\’s Free!

Its dysfunction leads to several neurodegenerative diseases such as schizophrenia, Parkinson s disease and drug addiction. Homology modeling, docking, classical molecular dynamics MD simulations and density functional theory DFT methods were used to investigate the unknown structure, dynamics and drug interactions of the dopamine D2 receptor.

The interaction of the modeled D2R with well known atypical and typical anti-psychotic drugs and the inhibition mechanisms of drugs at the catalytic domain were studied via atomistic molecular dynamic MD simulations. Their binding affinities and biological behaviors in the active site were elucidated.

The high and low affinity states of the D2 receptor models generated were then used as drug-binding targets to investigate binding interactions of dopamine and apomorphine.

The calculated Gibbs Free energies of binding were compared with the experimental dissociation constants4. The initial geometries of the drug-amino acid complexes were the MD poses which retrieved from previous MD studies1 equilibrated at biological temperature in the implicit water medium and then subjected to single point DFT calculations in the water using IEFPCM solvent model. The predicted D2R models were validated using different methods.

The structural differences between the active and inactive forms of the model D2R especially on the TM5 and TM6 sites were clearly indicated. The protein interactions and the binding efficiencies of targeted drugs were compared quantitatively. We observed that class-i and class-ii forms of atypical and typical D2R antagonists Figure 1. By superimposition, we were able to show distinct deviations between predicted active and inactive models of D2R monomer and also dimer at the TM6 site.


This domain in the active form moved outward from that in the inactive state in both the monomer and dimer conformers. Dashed lines indicate the salt bridge and H-bond interactions1. Iskit University of Hacettepe, Faculty of Medicine, Department of Pharmacology, Sihhiye, Ankara Biotechnological methods enable the development of novel biological medicinal products for many highly serious diseases and make it possible to create solutions for growing healthcare needs of the population.

Biologics or large molecules differ from chemical drugs or small molecules with respect to their manufacturing processes, size and complexity as well as origin, composition and nature. A biosimilar product is a biological product that has been developed to be substantially similar to an existing biological medicinal product the “reference, original product”.

Full text of “Acta eruditorum Anno Publicata”

After the expiration of patent and data protection periods of the reference biologic products, biosimilar products should be placed gaticaa the market. Biosimilars are not the same as generics copies of chemical medicineswhich have less complex chemical structures and which are considered to be the same as their reference products.

Unlike generic small molecule drugs, biosimilars are highly similar to the original medicine but not equivalent, therefore, the traditional generic drug pathway process is not appropriate for the development, regulatory assessment, licensing, prescribing and dispensing of such a biosimilar product. The regulatory pathways for biosimilars are stil evolving around the world with the U. International and national ;em have published numerous guidelines for biosimilars in recent years, which are continually updated.

Principally biosimilars should be analytically compared with gafica reference product to unwm and justify the differences, and the product’s safety and efficacy must be supported with clinical trials, including immunogenicity studies as high potential of immunogenicity is a major problem associated with these drugs.

Because a biosimilar product is not the same as the reference product, it is important to ensure that adverse events are regularly and accurately monitored. To ensure definitive identification of a suspect product, biological products should be clearly identifiable on the Adverse Event Report, with brand name and batch number information. For biosimiliars some additional pharmacovigilance and extra Risk Management Plan should be requested and extrapolation to other indications should be considered on a product-by-product basis for indications.

Patients must get the specific product which their physicians prescribed to them. The interchangeability or substitution at pharmacy of biosimilars will also be discussed in future as there are different approaches in Europe and the US.

Turkish Ministry of Health has a guideline regarding biosimilars. This guideline is not product-specific and covers all biosimilar products. According to the Decision of the Council of Ministers about State Aids in Investments; Investments above 20 million TL for biotechnological products including biosimilarsoncology drugs and blood products are considered as priority investment areas.

In conclusion, biosimilars provide an important treatment option for patients and healthcare policy yatica. Treatment decisions involving biosimilars should be centered on not the product’s price, but the best health outcomes for individual patients.

On the other hand, theranostic treatment is one of the most promising methods in cancer research, which simultaneously allows treating and the real-time monitoring of cancer. In order to obtain effective results for the treatment of cancer, appropriate drug dose and targeting in the desired region is very important as well as early diagnosis. Photodynamic therapy PDTconsidered as a promising and minimally-invasive treatment strategy, involves the participation of harmless visible light, photosensitizer, and tissue oxygen.

Working principle of PDT is to produce singlet oxygen radicals from tissue oxygen that cause damage of cell membrane structures, microvascular ischaemia, and tissue apoptosis. The basic problem of allosteric drug design is to identify residues that participate in allosteric communication and control and modify the gatjca of the protein by designing a drug molecule that interferes with this communication. Allosteric communication first requires the identification of two sites, the effector site, i.

Although more than allosteric sites are known many more need to be characterized. The second aspect of allosteric drug design is to find the proper ligand, which is already well studied by drug designers.